ISCOM-based vaccines: the second decade. (Q36062124)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

ISCOM-based vaccines: the second decade (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Megan T Sanders

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

Georgia Deliyannis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

Martin J Pearse

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

1 reference

1 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

Immunology & Cell Biology

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

volume

83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

119-128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748208 AND SRC:MED&resulttype=core&format=json

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Immune responses to ISCOM formulations in animal and primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Dendritic cell maturation enhances CD8 T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen: involvement of marginal metallophilic macrophages in the uptake of immune-stimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Induction of antibody responses in the common mucosal immune system by respiratory syncytical virus immunostimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Enhancement of IgG anti-carrier responses by IgG2 anti-hapten antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

IgG2a restriction of murine antibodies elicited by viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Cytotoxic T cell polyepitope vaccines delivered by ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8 t-cell-mediated immunity and protection against NY-ESO-1 tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

ISCOM based vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Vaccination prevents latent HSV1 infection of mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

The role of type-1 and type-2 T-helper immune responses in HIV-1 vaccine protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Immunogenic properties of ISCOM prepared with influenza virus nucleoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Iscom immunization with synthetic peptides representing measles virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles virus enables incorporation into ISCOMs and induction of CTL responses following intranasal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8( ) cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 and CD8 T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Antigenic determinants of influenza virus hemagglutinin. XII. the epitopes of a synthetic peptide representing the C-terminus of HA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Induction of long-term memory CD8( ) T cells for recall of viral clearing responses against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Induction of CD8 cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X

Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1440-1711.2005.01319.X